Sage Therapeutics
215 First Street
Cambridge
MA
02142
United States
Tel: 617-299-8380
Website: https://www.sagerx.com/
About Sage Therapeutics
Sage is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner.
Stock Symbol:
SAGE
372 articles about Sage Therapeutics
-
It was a particularly busy week for clinical trial announcements. Let's take a look. -
The 2022 American Academy of Neurology (AAN) Annual Meeting kicked off on Saturday and will continue on through Thursday. -
Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease
4/1/2022
Sage Therapeutics, Inc. announced the presentation of data from the Phase 2 LUMINARY Study that showed SAGE-718, a first-in-class, oral, positive allosteric modulator of the NMDA receptor, was generally well-tolerated and associated with improvement on multiple tests of executive performance and learning and memory in patients with mild cognitive impairment and mild dementia due to Alzheimer’s disease.
-
Sage Therapeutics to Present at 2022 Stifel CNS Days
3/22/2022
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that the Company will give a presentation at the 2022 Stifel CNS Days on Tuesday, March 29, 2022 at 4:00pm ET.
-
Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease
3/15/2022
Sage Therapeutics, Inc. announced the presentation of data that showed SAGE-718, a first-in-class, oral, positive allosteric modulator of the NMDA receptor, was associated with improvements on multiple tests of executive functioning and learning and memory in patients with mild cognitive impairment due to Parkinson’s disease in the open label Phase 2 PARADIGM Study.
-
Sage Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference
2/28/2022
Sage Therapeutics, Inc. announced that the Company will participate in a fireside chat at the Cowen 42nd Annual Healthcare Conference on Monday, March 7, 2022 at 10:30am ET.
-
Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
2/24/2022
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company fearlessly leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2021.
-
Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints
2/16/2022
Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced the CORAL Study in people with major depressive disorder (MDD) met the trial objectives.
-
Sage and Biogen announced positive topline results from the Phase III study of zuranolone that showed a rapid reduction in depressive symptoms after three days. -
Sage Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022
2/10/2022
Sage Therapeutics, Inc. today announced it will host a live webcast on Thursday, February 24, 2022 at 8:00 a.m. ET to announce fourth quarter and full year 2021 financial results and discuss recent business updates.
-
Another drug Vounatsos heralded was zuranolone, which Biogen is developing with Sage Therapeutics for multiple forms of depression. -
Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022
1/4/2022
Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022.
-
Sage Therapeutics’ Third Annual FutureCast Showcases Data from All Three Brain Health Franchises
12/14/2021
In the open-label LUMINARY Study, SAGE-718 improved performance from baseline on multiple tests of cognitive function in patients with Alzheimer’s disease mild cognitive impairment and mild dementia, consistent with positive signals seen in Parkinson’s disease and Huntington’s disease.
-
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress
12/8/2021
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new data from the LANDSCAPE clinical program evaluating the efficacy and safety of zuranolone for the treatment of major depressive disorder (MDD) presented at the American College of Neuropsychopharmacology (ACNP) Congress taking place December 5-8 in San Juan, Puerto Rico.
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look. -
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
12/1/2021
In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the study and nearly 80% received only one or two treatment courses in total.
-
The 12-month data showed that 50 mg of zuranolone was well-tolerated among adults with MDD. -
Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
11/24/2021
Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference.
-
Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
11/11/2021
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference.
